-
1
Vorinostat does not improve outcome in patients with acute myeloid leukemia and high risk myelodysplasia treated with azacitidine: Results of the UK Trials Acceleration Programme R...
Published 2016“…American Society of Hematology…”
Conference item -
2
Longitudinal mutational analysis in hydroxycarbamide-resistant/intolerant essential thrombocythemia treated on the majic-ET study
Published 2018“…American Society of Hematology…”
Conference item -
3
Correlation between treatment outcomes, baseline characteristics and molecular responses in the Majic study which compared Ruxolitinib to best available therapy in essential thromb...
Published 2016“…American Society of Hematology…”
Conference item -
4
Spliceosome mutations are common in MPN-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide
Published 2018“…American Society of Hematology…”
Conference item -
5
Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomized trial
Published 2017“…American Society of Hematology…”
Journal article